End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve participants, strengthening the case for a novel...
Hence then, the article about brii bio presents late breaking data from its ongoing phase 2 ensure study at easl congress 2025 suggesting brii 179 s role in advancing higher hbsag loss was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss )
Also on site :
- Driver dies in fiery freeway crash on Christmas Eve near Sacramento
- Trump’s Christmas Eve calls with children asking about Santa’s whereabouts are steeped in partisan politics
- Ukraine-Russia war latest: Zelensky awaits Putin response to new peace plan while Christmas Eve blast kills 3 in Moscow